Screening for Obesity Complications: Why BMI Fails to Detect Silent Liver Disease

Clinicians are shifting from basic body mass index (BMI) measurements to targeted waist-to-height ratios to identify hidden obesity complications. While BMI remains a simple, universally accessible tool, its primary limitation is its inability to distinguish between benign subcutaneous fat and highly toxic visceral fat surrounding vital organs. By contrast, waist-based metrics offer a brilliant, albeit indirect, proxy for visceral adiposity, allowing for a more nuanced assessment of metabolic risk.

The Hidden Danger of Asymptomatic Obesity Complications

Standard scales fail to identify visceral adiposity, the specific fat deposit linked to cardiovascular disease and type 2 diabetes. Within observed clinical cohorts, up to 75 per cent of individuals with obesity live with metabolic dysfunction-associated steatotic liver disease (MASLD).

To address this, clinicians are focusing on more precise anthropometric markers:

• Waist-to-height ratios to estimate visceral adiposity indirectly.
• Waist circumference measurements to better predict cardiovascular risk.

Because MASLD and its advanced form, MASH, produce no early symptoms, they frequently go undetected for years. Clinical estimates suggest that 12 to 40 per cent of patients with MASLD progress to MASH within an 8-to-13-year window. While waist metrics provide a superior, low-cost predictor of cardiovascular risk compared to BMI, they remain indirect approximations of internal organ health rather than definitive diagnostic tools.

Transitioning to waist-based screening could allow clinics to organise preventative care and manage liver health holistically before advanced disease takes hold. Whilst this anthropometric shift improves risk detection, it is only the first step in a broader, necessary overhaul of how we monitor metabolic health. Shifting the diagnostic centre of gravity away from weight scales could redefine how we manage chronic obesity.